Subsequent identification of the peptides found that a peptide fragment from C1RL was elevated in the urine of ccRCC patients, but showed decreasing expression in the urine of patients with higher grade disease, while GAPDHS, which was also reduced in ccRCC urine samples, showed increasing abundance in higher grade disease. This evidence concerns the gene C1RL and nonpapillary renal cell carcinoma.